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Background: Vancomycin-resistant Enterococcus (VRE) has been established as a significant health-care associated
problem since its first isolation in Australia in 1994. In this study, we measured the point prevalence and identified
risk factors associated with vanB VRE colonisation in a tertiary care hospital in Melbourne, Australia where VRE has
been endemic for 15 years.
Methods: A hospital-wide point prevalence survey was conducted on October 13, 2008 with colonisation detected
using rectal swab culture. Patient’s demographic and medical information was collected through a review of
medical records. Factors associated with VRE colonisation in univariate analysis were included in multivariate logistic
regression model to adjust for confounding.
Results: The prevalence of VRE colonisation on the day of screening was 17.5% (95% CI, 13.7 to 21.9). VRE was
detected from patients in each ward with the prevalence ranging from 3% to 29%. Univariate analysis showed the
use of any antibiotic, meropenem, ciprofloxacin, diarrhoea and longer length of hospital stay were associated with
increased risk of VRE colonisation (p<0.05). However, age, sex, proximity to VRE positive cases, use of other
antibiotics including cephalosporins, vancomycin were not associated with increased risk (P>0.05). Multivariate
analysis showed the exposure to meropenem (p=0.004), age (≥65 years) (p=0.036) and length of stay ≥7 days
(p<0.001) as independent predictors of VRE colonisation.
Conclusion: Our study suggests that exposure to antibiotics may have been more important than recent cross
transmission for a high prevalence of vanB VRE colonisation at our hospital.
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The emergence and spread of vancomycin-resistant
Enterococcus (VRE) in health care settings has added
risks and complexities in patient management. VRE
can cause a variety of health care-associated infections,
particularly bacteraemia and urinary tract infections.
Most enterococcal infections are caused by two species,
E. faecalis or E. faecium. VRE was first reported in Europe* Correspondence: allen.cheng@monash.edu
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reproduction in any medium, provided the orin 1986 and subsequently worldwide [1]. In Australia, the
first case of VRE was reported in 1994 and by 1998 from
all other major cities [2,3]. The predominant VRE genotype
circulating in Australia is E. faecium vanB, in contrast to
the vanA genotype which is predominant in the United
States and Europe [3,4]. Recent surveys have shown an in-
crease in the prevalence of vancomycin resistance in cli-
nical isolates of enterococci in Australia [5]. A VRE
prevalence as high as 19.1% was reported during an out-
break among hospital inpatients in Victoria [6]. Faecal co-
lonisation with VRE in the community has been
demonstrated in Australia but appears to be rare (preva-
lence 0.2%) although the vanB gene appears to be common
in commensal bacteria including Clostridium spp [7-9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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VRE colonisation including advanced age, severe under-
lying illness, inter-hospital transfer, nursing home resi-
dency, extended hospitalization, specialized nutritional
support, central venous catheterization, haematologic
malignant tumours, solid organ allograft, chronic
haemodialysis, antibiotic exposure to vancomycin, third-
generation cephalosporins, metronidazole, antibiotics
with anti-anaerobic activity, exposure to multiple anti-
biotics and prolonged duration of antibiotic therapy
[10]. However, most of those studies involve high risk
patients during outbreaks associated with vanA geno-
type. A previous study in Melbourne hospitals in 1998
identified broad spectrum antibiotics as significant risk
factor for new colonisation with vanB VRE [11].
VRE colonisation can lead to infections which prolong
hospital stay, increase the cost of care and increase mor-
bidity and mortality [12,13]. The identification of modifi-
able risk factors may assist in identifying targets for
intervention to reduce the incidence of VRE colonisation.
In this study, we measured the prevalence of VRE colon-
isation in a hospital-wide point prevalence survey. We
examined downstream risk factors for colonisation with
implications for VRE control policies, including antibiotic
exposure and patient placement, in a tertiary referral hos-
pital in Melbourne, Australia where vanB VRE has been
endemic for many years.Methods
Setting and study design
The Alfred hospital is a major tertiary teaching hospital
in Melbourne, Australia with 427 beds. The hospital
provides general services as well as broad range of spe-
cialist care including referral services for trauma, cystic
fibrosis and heart/lung transplantation, HIV/AIDS, bone
marrow transplantation as well as specialist intensive
care facilities.
We conducted a point prevalence survey on October 13,
2008 at the Alfred Hospital. All patients who were present
in the hospital (including inpatients, patients in the emer-
gency department, and day surgery but excluding psych-
iatry) at 8.00 a.m. were approached to participate. Patients
were provided with information sheets (including advice
about the potential consequences of VRE colonisation) and
verbal consent was obtained for participation. Patients were
included irrespective of known VRE status. Patients were
excluded if they were not able to consent, were for palliative
care only, had been discharged prior to being swabbed or
they declined to participate. Single rectal swabs were pri-
marily taken by nursing staff. Clinical data collection
included demographic details, bed location of all patients,
antibiotic use (at least 12 hours before the collection of rec-
tal swab in current admission), ICU exposure, and previoushospital admissions in patients that were found to be posi-
tive for VRE.
At the time of the survey, our VRE policy recommended
the screening of all ward patients where a new case of
VRE infection or colonisation was detected. There were
no systemic screening practices for patients in high risk
areas or testing of diarrhoeal stools prior to this study.
Patients with known VRE colonisation or infection were
isolated in single rooms with a dedicated toilet if they had
faecal incontinence or diarrhoea. Healthcare workers were
required to use gloves when entering the room, and gloves
and gown if contact with body fluids was anticipated. Hos-
pital floors were cleaned daily with 1000 part per million
(ppm) sodium hypochlorite.
A nested case control (1:2) study was conducted to
identify risk factors associated with VRE colonisation. A
case was defined as a patient confirmed to be positive by
standard microbiological methods for VRE isolated from
rectal swabs taken for the point prevalence survey. A
control was defined as a patient confirmed to be nega-
tive for VRE colonisation on the same survey. For each
case, two unmatched controls were selected at random
from eligible patients.
Microbiology
Rectal swabs were taken either by the patients them-
selves following instruction, or by nursing staff. The
swabs were then plated onto bile aesculin media (BBL
Enterococcosel agar, Cockeysville, MD) with vancomycin
6 μg/mL and incubated at 37°C for up to 72 hours. En-
terococci species were identified using the VITEK-2 sys-
tem (bioMérieux). Polymerase chain reaction was used
to detect the vanA or vanB genes as described previ-
ously. [14] VRE colonisation was defined if an isolate of
E. faecalis or E. faecium with vanA or vanB gene was
detected. Ribotyping of the isolates was performed using
the Riboprinter Microbial Characterization system as
previously described [15,16].
Statistical methods
Standard statistical methods were used to summarize
categorical and continuous measures and to compare
proportions. Univariate analysis was performed to calcu-
late unadjusted odds ratio. All variables with a p-value of
<0.2 in univariate analysis were included in the multiple
logistic regression model to examine independently asso-
ciated risk factors for VRE colonisation. The association
was considered statistically significant if p<0.05. Statis-
tical analyses were performed using Stata statistical soft-
ware (Version 10; Stata Corp, College Station, Texas).
Ethics
As this VRE survey represented a quality assurance ac-
tivity, we did not obtain a formal ethical approval to
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selled patients about the significance of VRE and pro-
vided written information, and obtained verbal consent
to take rectal swabs from all patients and/or their rela-
tives. We obtained approval from the Alfred Health
Human Research Ethics Committee and Monash Uni-
versity Human Research Ethics Committee to retrieve
demographic and clinical information from the medical
records of patients for the case control study.Results
A total of 434 patients were present in hospital at the
time of survey. Among the total, 331 (77%) were
screened for VRE colonisation; 103 patients (23%) could
not be screened either due to refusal, discharge from
hospital prior to the time of swabbing, patients not being
present in the ward at the time of screening, or if the pa-
tient was for palliative care.Table 1 Factors associated with VRE detection in cases and co
Variables Cases
Participants 58
Age ≥ 65 (years) 35 (60.3%)
Male 36 (62.1%)
Antibiotics
Exposure to any antibiotic 45 (77.6%)
Meropenem 8 (13.8%)
Antibiotics other than meropenem 39 (67.2%)
Vancomycin 13 (22.4%)
Teicoplanin 2 (3.4%)












ICU admission 18 (31.1%)
Within 2 rooms of positive case 30 (62.5%)
On same side as positive case 48 (82.8%)
Diarrhoea 12 (21.1%)
Length of stay (Median days) 11.5 (7–30)
Length of stay ≥7 days 43 (74.2%)The prevalence of VRE colonisation on the day of
screening was 58 of 331 patients (17.5%, 95% CI, 13.7%
to 21.9%). The proportion of patients colonised with
VRE was 3% in the emergency department and ranged
from 8% to 29% in inpatient wards. Of the 58 VRE iso-
lates, 57 were found to be Enterococcus faecium and one
was Enterococcus faecalis. All the isolates were positive
for vanB resistance genotype and no vanA resistance geno-
type was detected. All together, 9 ribotypes were detected
with the majority of isolates belonging to either of the two
ribotypes (S-7, n=25, 43%; S-5, n=23, 39%). However, more
than 1 ribotype was present in all wards where there was
more than one VRE-colonised patient present.
Of the total 58 patients found to be VRE colonised, 46
(79.3%) were not previously known to be VRE colonised
and 12 (20.7%) were known to be previously colonised.
A further 13 patients had a history of VRE colonisation
but VRE was not detected on screening at the time of
the survey.ntrols (Univariate analysis)
Controls Unadjusted OR P value
116 - -
56 (48.2%) 1.63 (0.82 to 3.26) 0.13
74 (63.8%) 0.92 (0.46 to 1.88) 0.82
55 (47.4%) 3.83 (1.79 to 8.54) <0.001
2 (1.7%) 9.12 (1.71 to 89.92) 0.001
54 (46.5%) 4.5 (2.06 to 10.71) 0.001
19 (16.38%) 1.47 (0.61 to 3.46) 0.33
2 (1.7%) 2.03 (0.14 to 28.63) 0.47
32 (27.6%) 1.27 (0.60 to 2.66) 0.47
24 (20.7%) 0.89 (0.36 to 2.11) 0.78
0 - -
4 (3.4%) 2.64 (0.54 to 13.79) 0.14
6 (5.2%) 0.32 (0.01 to 2.76) 0.27
19 (16.4%) 0.48 (0.13 to 1.43) 0.16
9 (7.8%) 2.78 (0.96 to 8.11) 0.03
12 (10.3%) 2.02 (0.74 to 5.41) 0.11
3 (2.6%) 0.66 (0.01 to 8.45) 0.72
9 (7.8%) 0.42 (0.04 to 2.16) 0.27
3 (2.6%) 3.55 (0.65 to 23.53) 0.07
26 (22.4%) 1.55 (0.71 to 3.33) 0.21
54 (65.8%) 0.86 (0.38 to 1.94) 0.69
83 (77.6%) 1.38 (0.57 to 3.53) 0.43
11 (9.5%) 2.54 (0.94 to 6.85) 0.03
6.0 (3–13) - <0.001
43 (37.1%) 4.86 (2.30 to 10.51) <0.001
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We compared the exposure to probable risk factors in
58 cases and 116 controls.
Significantly higher proportions of cases had prior ex-
posure to one or more antibiotics (odds ratio (OR) 3.83,
95% CI 1.79 to 8.54). Similarly, cases had a longer length
of hospital stay compared to controls (P<0.001). Patients
with VRE colonisation were more likely to have been ad-
mitted for ≥7 days (OR 4.86, 95% CI 2.30 to 10.51). Uni-
variate analyses identified prior exposure to any
antibiotic (p <0.001), exposure to meropenem (p=0.001),
ciprofloxacin (p=0.03), diarrhoea (p=0.03) as associated
with the detection of VRE colonisation (Table 1). How-
ever, the prior use of vancomycin (p=0.33), ticarcillin-
clavulanate (p=0.11), pipericillin-tazobactam (p=0.07),
metronidazole (p=0.16) and any cephalosporins were not
associated with colonisation status. Proximity to other
VRE positive cases either in same side of the ward or
located within next 2 rooms was not associated with
VRE colonisation (p>0.05) (Table 1).
In a multivariate logistic regression model, exposure to
meropenem (adjusted OR; 12.24, 95% CI 2.24 to 66.77),
age ≥ 65years (adjusted OR 2.19, 95% CI 1.05 to 4.58)
and length of stay ≥7 days (adjusted OR 4.69, 95% CI
2.25 to 9.73) were independently associated with VRE
colonisation (Table 2). After adjusting for age ≥ 65years,
length of stay ≥7 days and exposure to meropenem, ex-
posure to any antibiotic other than meropenem (com-
pared to patients that did not receive any antibiotics)
was independently associated with VRE colonisation
(adjusted OR 2.95, 95% CI 1.27 to 6.88). In total, 16
(9.2%) patients in case–control study were from emer-
gency department and short stay units. A sensitivity ana-
lysis excluding the patients in these units did not alter
any of the above effects, significantly.
Discussion
We conducted a hospital-wide point prevalence survey
to measure the prevalence of VRE, as our previous sur-
veillance activities were targeted to patients felt to be at
risk and therefore may have resulted in selection biases.
In this survey, we confirmed that vanB VRE is endemic
in inpatients at our hospital. We found a lower preva-
lence in short stay areas, such as the emergency de-
partment (3%) and the short stay unit, but prevalence
was 8-29% in other inpatient areas. This is higher thanTable 2 Factors associated with VRE detection in cases
and controls (multivariate analysis)
Risk factor Adjusted OR (95% CI) p value
Meropenem 12.24 (2.24 to 66.77) 0.004
Age (≥65 years) 2.19 (1.05 to 4.58) 0.036
Length of stay ≥7 days 4.69 (2.25 to 9.73) <0.001reported by previous studies conducted at Melbourne
hospitals [11,17-19]. This is also in contrast to previous
studies demonstrating that VRE colonisation was
restricted to particular high risk inpatient areas [11].
Our finding that 80% of the VRE colonised patients in
the survey were newly detected cases demonstrates that
the previous screening strategy of surveying patients
only on wards when a new clinical isolate of VRE was
detected is inadequate.
Prima facie, our results suggest that antibiotic selec-
tion pressures appear to play a larger role in determining
VRE colonisation than cross-transmission at our institu-
tion. Exposure to antibiotics, particularly meropenem,
was strongly associated with VRE colonisation; this is
consistent with previous studies suggesting that anti-
biotic regimens with activity against anaerobic bacteria
are potent risk factors in the development of VRE
[20-22]. The vanB gene is known to be present in com-
mensal enteric bacteria such as Clostridium, and trans-
mission of this gene to E. faecium has been
demonstrated in vivo [23]. In other studies, a variety of
other antibiotics have been implicated as risk factors for
VRE colonisation, including vancomycin, metronidazole,
piperacillin-tazobactam, ticarcillin-clavulanate and third
generation cephalosporins [24-26]. However, our analysis
comparing meropenem and non-meropenem antibiotic
use with no antibiotic use showed the exposure to anti-
biotics other than meropenem is also associated with
VRE colonisation. Thus, our study may have been under-
powered to detect differences at the level of individual
antibiotics other than meropenem.
We found ambiguous evidence regarding the extent of
cross transmission of VRE, which has been shown to be
important in previous studies [27,28]. We did not find
proximity to other VRE colonised patients to be a risk fac-
tor for VRE detection. However, this does not exclude the
possibility of cross transmission contributing to endem-
icity, as transmission may have occurred prior to the time
of the survey and would not be detected with frequent pa-
tient movements. Conversely, the finding that ribotyping
only demonstrated two large clones of VRE in patients
does not necessarily implicate extensive cross transmis-
sion. If transmission was significant, we would expect a
lower diversity among individual wards; however, we
found that in all wards with at least two VRE colonised
patients had at least two ribotypes. We did not have access
to pulsed field gel electrophoresis, regarded as the gold
standard for epidemiological investigations of VRE [29].
The purpose of this study was to examine “down-
stream” exposures that had implications for VRE control
policies, rather than patient-specific “upstream” risk fac-
tors that are not modifiable. However, we did find older
age and longer length of stay in hospital as independent
predictor of VRE colonisation. This is reflected in the
Karki et al. Antimicrobial Resistance and Infection Control 2012, 1:31 Page 5 of 6
http://www.aricjournal.com/content/1/1/31low colonisation rate in patients with a short length of
stay, including emergency and short stay units.
A strength of this study is that we conducted a
hospital-wide survey including a broad range of patients,
thus minimizing selection biases [30]. A limitation of
this cross-sectional study is that we were not able to de-
termine the timing of acquisition of VRE in the patients
identified as being colonised; therefore, patients may
have acquired VRE in the remote past, with antibiotic
use merely amplifying existing colonisation. In addition,
we do not have data on patient co-morbidities, previous
invasive procedures, and indwelling devices, which may
have confounded our findings. We chose to perform rec-
tal swabs due to practical reasons but previous studies
have demonstrated that the sensitivity of these speci-
mens is around 79%, we might have missed detection of
few patients with low VRE density [31,32]. We did not
perform separate broth enrichment before the agar plate
culture, which may lead to an underestimation of the
true prevalence [33]. This may have resulted in mis-
classification bias in assigning VRE colonised patients as
controls and bias the case control study towards the null
hypothesis. As the sensitivity of VRE detection is likely
to be related to bacterial density, it is likely that detec-
tion of VRE in screening is the product of two processes,
that of new acquisition of VRE (whether by endogenous
generation or exogenous exposure) and amplification of
existing low level colonisation by antibiotics [34].Conclusions
The endemic and high prevalence of vanB VRE in our set-
ting may have been maintained by higher exposure to anti-
biotics. Although cross transmission remains a possibility
and is supported by predominance of two large clones of
VRE, colonisation status did not appear to be associated
with proximity to other colonised patients. Our data sug-
gest that antibiotic stewardship efforts may be more effect-
ive in reducing the spread of VRE in our hospital.
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